SLC5A2 and type 2 diabetes mellitus: A meta-analysis of four randomised controlled trials found the relative risk (RR) of DKA in participants with type 2 diabetes treated with SGLT2 inhibitors vs placebo or active comparator arm to be 2.46 (95% CI 1.16, 5.21), while a meta-analysis of five observational studies found the RR to be 1.74 (95% CI 1.07, 2.83) [94].